Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, August 9, 2022
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
Madhu Kumar Maintained (APLS) at Strong Buy with Increased Target to $102 on, Aug 9th, 2022
Madhu Kumar of Goldman Sachs, Maintained "Apellis Pharmaceuticals, Inc." (APLS) at Strong Buy with Increased Target from $91 to $102 on, Aug 9th, 2022.
Madhu has made no other calls on APLS in the last 4 months.
There are 3 other peers that have a rating on APLS. Out of the 3 peers that are also analyzing APLS, 0 agree with Madhu's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Madhu
- Yigal Nochomovitz of "Citigroup" Maintained at Strong Buy with Increased Target to $86 on, Wednesday, July 20th, 2022
- Douglas Tsao of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $75 on, Tuesday, July 19th, 2022
- Elemer Piros of "Roth Capital" Downgraded from Hold to Strong Sell and Held Target at $40 on, Thursday, April 14th, 2022
